The Clinical Management of Cholangiocarcinoma in the United States and Europe: A Comprehensive and Evidence-Based Comparison of Guidelines

• Published in: Annals of surgical oncology Vol. 28; no. 5; pp. 2660 - 2674
• Main Authors: Fong, Zhi Ven, Brownlee, Sarah A., Qadan, Motaz, Tanabe, Kenneth K.
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.05.2021; Springer Nature B.V
• Subjects: Bile Duct Neoplasms - therapy; Bile Ducts, Intrahepatic; Biopsy; Cholangiocarcinoma; Cholangiocarcinoma - epidemiology; Cholangiocarcinoma - therapy; Cisplatin; Clinical trials; Discordance; Europe; Gastroenterology; Gemcitabine; Hepatobiliary Tumors; Humans; Jaundice; Klatskin Tumor; Liver cancer; Medicine; Medicine & Public Health; Oncology; Patients; Positron emission tomography; Standardization; Surgery; Surgical Oncology; Survival; United States - epidemiology; United States; Europe; United States > US
• ISSN: 1068-9265; 1534-4681
• DOI: 10.1245/s10434-021-09671-y

Background The incidence of cholangiocarcinoma has doubled over the last 15 years with a similar rise in mortality, which provides the impetus for standardization of evidence-based care through the establishment of guidelines. Methods We compared available guidelines on the clinical management of cholangiocarcinoma in the United States and Europe, which included the National Comprehensive Cancer Network (NCCN), European Society for Medical Oncology (ESMO), British Society of Gastroenterology (BSG) and the International Liver Cancer Association (ILCA) guidelines. Results There is discordance in the recommendation for biopsy in patients with potentially resectable cholangiocarcinoma and in the recommendation for use of fluorodeoxyglucose positron emission tomography scans. Similarly, the recommendation for preoperative biliary drainage for extrahepatic and perihilar cholangiocarcinoma in the setting of jaundice is inconsistent across all four guidelines. The BILCAP (capecitabine) and ABC-02 trials (gemcitabine with cisplatin) have provided the strongest evidence for systemic therapy in the adjuvant and palliative settings, respectively, but all guidelines have refrained from setting them as standard of care, given heterogeneity in the study cohorts and ABC-02’s negative intention-to-treat results. Conclusions Future progress in enhancing survivorship of patients with cholangiocarcinoma would likely entail improvements in diagnostic biomarkers and novel systemic therapies. Based on recent results from studies of targeted therapy, future iterations of the guidelines will likely incorporate molecular profiling.